Efficiency of Cisplatin Based Concurrent Chemoradiation in Stages III & IV Head & Neck Squamous Cell Carcinoma
Keywords:
Head & neck cancer, cisplatin, chemoradiationAbstract
Objective:
To determine the response of cisplatin-based concurrent chemoradiation in stages III and IV head & neck squamous cell cancer and to evaluate frequency of common toxicities.
Introduction:
Almost 70% of head and neck cancer patients present with locally advanced disease (stage III and IV). Concurrent chemoradiotherapy is the current standard treatment. Cytotoxic cisplatin is the treatment of choice for concomitant chemoradiotherapy. Cisplatin acts as a radiation sensitizer and advances the antitumor efficacy when combined with radiotherapy. Likewise all chemotherapeutic agents also show side effects including mucositis, dermatitis, nausea & diarrhea.
Materials & Methods:
A descriptive study conducted in Department of Radiotherapy, Karachi Institute of Radiotherapy and Nuclear Medicine from 2010 to 2011. Fractions with 2 Gy per fraction were completed in 7 weeks. Sample size of 85 enrolled. Total dose of radiotherapy was 66 Gy in 33 fractions. Cisplatin of 100 mg /m² on day 1, 22 and 43 were given. Treatment response was determined radiologically at four weeks. Toxicity was assessed weekly during treatment.
Results:
Mean age was 55.4 (±10.5) years with Male to Female ratio was 1.3: 1. Thirty (41.1%) patients had achieved complete response (CR), 36 (49.3%) patients had partial response (PR). Significant response rate was 90.4%. p-value was significant <0.05. Most common toxic effects were mucositis 72.6%, vomiting 68.5%, moderate dermatitis 64.4% followed by mild diarrhea 60.3% and dry mouth 54.8%. Overall response of cisplatin was good.
Conclusion: A significant response of cisplatin-based chemoradiation achieved. Mucositis was found the most common toxic effect.
Downloads
References
Merchant A, Hussain SS, Hosain M, Fikree FF, Pitiphat W, Siddiqui AR, et al. Paan without tobacco: an independent risk factor for oral cancer. Int J Cancer 2000; 86:128-31.
Hanif M, Zaidi P, Kamal S, Hameed A. Institution based cancer incidence in a local population in Pakistan: nine year data analysis. As Pacific J Cancer Prev 2009; 10:1-4.
Nagar YS, Singh S, Datta NR. Chemo-reirradiation in Persistent/Recurrent Head and Neck Cancers. Jpn J Clin Oncol 2004; 34:61–8.
Kim Y, Kim B, Jung S, Lee Y, Kim M, Sun D, et al. Radiation therapy combined with (or without) cisplatin-based chemotherapy for patients with nasopharyngeal cancer: 15-years’ experience of a single institution in Korea. Cancer Res Treat 2008; 40:155-63.
Posner MR, Diane M. Hershock DM, Cesar R. Blajman CR, Mickiewicz E, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705-15.
Bhide SA, Ahmed M, Barbachano Y, Harrington KJ, Nutting CM. Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer. Br J Cancer 2008; 99:57- 62.
Argiris A, Haraf DJ, Kies MS, Vokes EE. Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil- and hydroxyurea-based regimens: Reversing a pattern of failure. Oncologist 2003; 8:350-60.
Soo KC, Tan EH, Wee J, Lim D, Tai BC, Khoo ML. et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison Br J Cancer 2005; 93:279-86.
Adelstein DJ. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent hemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21:92-8.
Masud AI, Mahmood Q, Siddique N. Unresectable head and neck carcinomas; concomitant chemo-radiotherapy with cisplatin and 5-flourouracil. Professional Med J 2007; 14:112-19.
Eisenhauera EA, Therasseb P, Bogaertsc J, Schwartzd LH, Sargente D, Fordf R. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Europ Cancer 2009; 45:228-47.
Browman GP. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis. Head Neck 2001; 23:579-89.
Garden AS. Preliminary results of radiation therapy oncology group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004; 22:2856-64.
Adelstein DJ. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 2006; 24:1064-71.
Bernier J. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945-52.
Cooper JS. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937-44.
Jain RK, Kirar P, Gupta G, Dubey S, Gupta S, Goyal J. A comparative study of low dose weekly paclitaxel versus cisplatin with oncurrent radiation in the treatment of locally advanced head and neck cancers. Ind J Cancer. 2009; 46:50-3.
Zenda S, Onozawa Y, Tahara M, Kawashima M, Shikama N, Sasaki S, et al. Feasibility study of single agent cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of The head and neck: preliminary results. Jpn J Clin Oncol. 2007;37:725-9.
Vokes E, Kies M, Haraf D, Stenson K, List M, Humerickhouse R, et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000; 18:1652-61.
Poole ME, Sailer S, Rosenman J, Tepper J, Weissler M. Chemoradiation for locally advanced squamous cell carcinoma of the head and neck for organ preservation and palliation. Arch Otolaryngol Head Neck Surg. 2001; 127:1446-50.
Hung S, Chen H, Hsieh C, Hsu W, Chang K, Chen Y, et al. Concurrent chemoradiotherapy versus radiotherapy alone for ypopharyngeal cancer, Chin J Radiol 2006; 31:77-84.
Essa HH, Azzam M. Concurrent chemoradiation in locally advanced head and neck cancers: a comparative study of weekly paclitaxel versus cisplatin-based regimen. J Egypt Natl Canc Inst 2010; 22:165-73.
Acharya B, Manandhar T, Jha Ak. Effect of concurrent chemoradiation therapy in patients with locally advanced unresectable head and neck cancer. PMJN 2088; 8.
Sunwoo J, Herscher L, Kroog G, Thomas G, Ondrey F, Duffey D, et al. Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol 2001; 3:800-1.
Lövey J, Koronczay K, Remenár E, Csuka O, Németha G. Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer. Radiother Oncol. 2003; 68:171-4.
Merlano M, Vitale V, Rosso R. Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Eng J Med 1992; 327:1115-21.
Henk JM. Controlled trials of synchronous chemotherapy with radiotherapy in head and neck cancer: overview of radiation morbidity. Clin Oncol 1997; 9:308-12.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Syeda Uzma Naqvi, Kulsoom Begum, Akhtar Ahmed, Syed Amir Maqbool
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Articles published in the Journal of Dow University of Health Sciences are distributed under the terms of the Creative Commons Attribution Non-Commercial License https://creativecommons.org/ licenses/by-nc/4.0/. This license permits use, distribution and reproduction in any medium; provided the original work is properly cited and initial publication in this journal. 
